{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:03:59Z","timestamp":1788318239432,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cathepsin D (CTSD) is a lysosomal aspartic protease that plays vital roles in regulating the properties of solid tumors, including proliferation, apoptosis, migration, metastasis, and angiogenesis. However, the function of CTSD in haematological malignancies remains largely elusive. Here we show that CTSD is highly expressed in acute myeloid leukemia (AML) and that high CTSD expression is associated with unfavourable prognosis. Knockdown of <jats:italic>CTSD<\/jats:italic> in AML cells inhibits cell proliferation and anti-apoptotic activity. Mechanistically, CTSD decreased the expression of the E3 ubiquitin ligase TRIM21, which mediates the ubiquitination and degradation of anti-apoptotic proteins BCL2, BCL-XL, and MCL1. Inhibition of CTSD expression via genetics or the small-molecule inhibitor <jats:bold>N-8<\/jats:bold> decreases the protein levels of BCL2, BCL-XL, and MCL1 through accelerating their degradation. <jats:bold>N-8<\/jats:bold> shows significant efficacy in eradicating AML in both venetoclax-sensitive and -resistant models. Collectively, our study reveals the role of CTSD in leukemia progression and highlights targeting CTSD as a potential therapeutic strategy in AML.<\/jats:p>","DOI":"10.1038\/s41419-025-07949-7","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:25:18Z","timestamp":1755005118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cathepsin D promotes acute myeloid leukemia progression through stabilization of the anti-apoptotic proteins"],"prefix":"10.1038","volume":"16","author":[{"given":"Huimin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Churan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5148-6484","authenticated-orcid":false,"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4062-3096","authenticated-orcid":false,"given":"Shujuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Situ","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-8849","authenticated-orcid":false,"given":"Jian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7444","authenticated-orcid":false,"given":"Zhuorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-6308","authenticated-orcid":false,"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"7949_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Prim. 2016;2:16010.","journal-title":"Nat Rev Dis Prim"},{"key":"7949_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"7949_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"7949_CR4","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1182\/blood.V128.22.5259.5259","volume":"128","author":"Z Ping","year":"2016","unstructured":"Ping Z, McIntosh ER, Tao G, Shen D, Reddy V. Prognostic Genomic Biomarkers for Acute Myeloid Leukemia (AML) Based on French-American-British (FAB) Subtypes. Blood. 2016;128:5259.","journal-title":"Blood"},{"key":"7949_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bjhh.2014.11.008","volume":"37","author":"SL Padilha","year":"2015","unstructured":"Padilha SL, Souza EJ, Matos MC, Domino NR. Acute myeloid leukemia: survival analysis of patients at a university hospital of Paran\u00e1. Rev Bras Hematol Hemoter. 2015;37:21\u20137.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"7949_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5:288.","journal-title":"Signal Transduct Target Ther"},{"key":"7949_CR7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375.","journal-title":"Cancer Discov"},{"key":"7949_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"7949_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Cancer Cell. 2018;34:879\u201391.","journal-title":"Cancer Cell"},{"key":"7949_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov. 2019;9:342\u201353.","journal-title":"Cancer Discov"},{"key":"7949_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D, Jourdain AA, Hern\u00e1ndez-S\u00e1nchez M, Martinez Zurita A, et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019;36:369\u201384.","journal-title":"Cancer Cell"},{"key":"7949_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019;9:910\u201325.","journal-title":"Cancer Discov"},{"key":"7949_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","volume":"68","author":"P Benes","year":"2008","unstructured":"Benes P, Vetvicka V, Fusek M. Cathepsin D\u2013many functions of one aspartic protease. Crit Rev Oncol Hematol. 2008;68:12\u201328.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7949_CR14","doi-asserted-by":"crossref","unstructured":"Yadati T, Houben T, Bitorina A, Shiri-Sverdlov R. The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. Cells. 2020;9:1679.","DOI":"10.3390\/cells9071679"},{"key":"7949_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1080\/15548627.2020.1752497","volume":"17","author":"YQ Di","year":"2021","unstructured":"Di YQ, Han XL, Kang XL, Wang D, Chen CH, Wang JX, et al. Autophagy triggers CTSD (cathepsin D) maturation and localization inside cells to promote apoptosis. Autophagy. 2021;17:1170\u201392.","journal-title":"Autophagy"},{"key":"7949_CR16","doi-asserted-by":"publisher","first-page":"28084","DOI":"10.18632\/oncotarget.4394","volume":"6","author":"AS Bach","year":"2015","unstructured":"Bach AS, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, et al. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells. Oncotarget. 2015;6:28084\u2013103.","journal-title":"Oncotarget"},{"key":"7949_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04581-7","volume":"13","author":"SU Seo","year":"2022","unstructured":"Seo SU, Woo SM, Im SS, Jang Y, Han E, Kim SH, et al. Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization of Bcl-xL in cancer cells. Cell Death Dis. 2022;13:115.","journal-title":"Cell Death Dis"},{"key":"7949_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2018.09.021","volume":"438","author":"C Zhang","year":"2018","unstructured":"Zhang C, Zhang M, Song S. Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation. Cancer Lett. 2018;438:105\u201315.","journal-title":"Cancer Lett"},{"key":"7949_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jso.1093","volume":"77","author":"M Ikeguchi","year":"2001","unstructured":"Ikeguchi M, Fukuda K, Oka S, Hisamitsu K, Katano K, Tsujitani S, et al. Micro-lymph node metastasis and its correlation with cathepsin D expression in early gastric cancer. J Surg Oncol. 2001;77:188\u201394.","journal-title":"J Surg Oncol"},{"key":"7949_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ygyno.2003.11.016","volume":"92","author":"A L\u00f6sch","year":"2004","unstructured":"L\u00f6sch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol. 2004;92:545\u201352.","journal-title":"Gynecol Oncol"},{"key":"7949_CR21","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1158\/0008-5472.CAN-07-6276","volume":"68","author":"L Hu","year":"2008","unstructured":"Hu L, Roth JM, Brooks P, Luty J, Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res. 2008;68:4666\u201373.","journal-title":"Cancer Res"},{"key":"7949_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18935-2","volume":"11","author":"S Ketterer","year":"2020","unstructured":"Ketterer S, Mitschke J, Ketscher A, Schlimpert M, Reichardt W, Baeuerle N, et al. Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling. Nat Commun. 2020;11:5133.","journal-title":"Nat Commun"},{"key":"7949_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40425-019-0498-z","volume":"7","author":"Y Ashraf","year":"2019","unstructured":"Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, et al. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7:29.","journal-title":"J Immunother Cancer"},{"key":"7949_CR24","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","volume":"111","author":"JC Reed","year":"2008","unstructured":"Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322\u201330.","journal-title":"Blood"},{"key":"7949_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28:20\u201338.","journal-title":"Apoptosis"},{"key":"7949_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120\u20135.","journal-title":"Genes Dev"},{"key":"7949_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","volume":"5","author":"L Deng","year":"2020","unstructured":"Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11.","journal-title":"Signal Transduct Target Ther"},{"key":"7949_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471:104\u20139.","journal-title":"Nature"},{"key":"7949_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-146","volume":"12","author":"H Ren","year":"2013","unstructured":"Ren H, Koo J, Guan B, Yue P, Deng X, Chen M, et al. The E3 ubiquitin ligases \u03b2-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. Mol Cancer. 2013;12:146.","journal-title":"Mol Cancer"},{"key":"7949_CR30","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","volume":"121","author":"Q Zhong","year":"2005","unstructured":"Zhong Q, Gao W, Du F, Wang X. Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005;121:1085\u201395.","journal-title":"Cell"},{"key":"7949_CR31","doi-asserted-by":"crossref","unstructured":"Edison N, Curtz Y, Paland N, Mamriev D, Chorubczyk N, Haviv-Reingewertz T, et al. Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis. Cell Rep. 2017;21:442\u201354.","DOI":"10.1016\/j.celrep.2017.09.052"},{"key":"7949_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s43018-021-00177-w","volume":"2","author":"M Hashimoto","year":"2021","unstructured":"Hashimoto M, Saito Y, Nakagawa R, Ogahara I, Takagi S, Takata S, et al. Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia. Nat Cancer. 2021;2:340\u201356.","journal-title":"Nat Cancer"},{"key":"7949_CR33","doi-asserted-by":"publisher","first-page":"e2762","DOI":"10.1073\/pnas.1716439115","volume":"115","author":"Y Wu","year":"2018","unstructured":"Wu Y, Li X, Jia J, Zhang Y, Li J, Zhu Z, et al. Transmembrane E3 ligase RNF183 mediates ER stress-induced apoptosis by degrading Bcl-xL. Proc Natl Acad Sci USA. 2018;115:e2762\u2013e71.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7949_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neo.2016.12.006","volume":"19","author":"Y Gong","year":"2017","unstructured":"Gong Y, Schumacher SE, Wu WH, Tang F, Beroukhim R, Chan TA. Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia. 2017;19:75\u201383.","journal-title":"Neoplasia"},{"key":"7949_CR35","first-page":"33","volume":"109","author":"GLQ Tang","year":"2024","unstructured":"Tang GLQ, Lai JXH, Pervaiz S. Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches. Haematologica. 2024;109:33\u201343.","journal-title":"Haematologica"},{"key":"7949_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.267","volume":"4","author":"L Kakkola","year":"2013","unstructured":"Kakkola L, Denisova OV, Tynell J, Viili\u00e4inen J, Ysenbaert T, Matos RC, et al. Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. Cell Death Dis. 2013;4:e742.","journal-title":"Cell Death Dis"},{"key":"7949_CR37","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","volume":"24","author":"S Arai","year":"2018","unstructured":"Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL\/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res. 2018;24:5458\u201370.","journal-title":"Clin Cancer Res"},{"key":"7949_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.chembiol.2023.06.023","volume":"30","author":"D Benton","year":"2023","unstructured":"Benton D, Chernoff J. TRIMming away colon cancer: TRIM21-mediated ubiquitination as an activator of the Hippo tumor suppressor pathway. Cell Chem Biol. 2023;30:699\u2013701.","journal-title":"Cell Chem Biol"},{"key":"7949_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1204","volume":"13","author":"C Sampson","year":"2023","unstructured":"Sampson C, Wang Q, Otkur W, Zhao H, Lu Y, Liu X, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin Transl Med. 2023;13:e1204.","journal-title":"Clin Transl Med"},{"key":"7949_CR40","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/modpathol.2016.128","volume":"29","author":"JY Choe","year":"2016","unstructured":"Choe JY, Park M, Yun JY, Na HY, Go H, Kim HJ, et al. PELI1 expression is correlated with MYC and BCL6 expression and associated with poor prognosis in diffuse large B-cell lymphoma. Mod Pathol. 2016;29:1313\u201323.","journal-title":"Mod Pathol"},{"key":"7949_CR41","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/1878-0261.13134","volume":"16","author":"D Dai","year":"2022","unstructured":"Dai D, Zhou H, Yin L, Ye F, Yuan X, You T, et al. PELI1 promotes radiotherapy sensitivity by inhibiting noncanonical NF-\u03baB in esophageal squamous cancer. Mol Oncol. 2022;16:1384\u2013401.","journal-title":"Mol Oncol"},{"key":"7949_CR42","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","volume":"26","author":"SB Balachander","year":"2020","unstructured":"Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P, et al. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x(L), Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. Clin Cancer Res. 2020;26:6535\u201349.","journal-title":"Clin Cancer Res"},{"key":"7949_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1568009616666161229145115","volume":"17","author":"V Dubey","year":"2017","unstructured":"Dubey V, Luqman S. Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents. Curr Cancer Drug Targets. 2017;17:404\u201322.","journal-title":"Curr Cancer Drug Targets"},{"key":"7949_CR44","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1038\/sj.onc.1205745","volume":"21","author":"G Berchem","year":"2002","unstructured":"Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene. 2002;21:5951\u20135.","journal-title":"Oncogene"},{"key":"7949_CR45","doi-asserted-by":"publisher","first-page":"68180","DOI":"10.18632\/oncotarget.19254","volume":"8","author":"L Yang","year":"2017","unstructured":"Yang L, Cui M, Zhang L, Song L. FOXM1 facilitates gastric cancer cell migration and invasion by inducing Cathepsin D. Oncotarget. 2017;8:68180\u201390.","journal-title":"Oncotarget"},{"key":"7949_CR46","doi-asserted-by":"publisher","first-page":"16517","DOI":"10.18632\/oncotarget.4140","volume":"6","author":"T Gemoll","year":"2015","unstructured":"Gemoll T, Epping F, Heinrich L, Fritzsche B, Roblick UJ, Szymczak S, et al. Increased cathepsin D protein expression is a biomarker for osteosarcomas, pulmonary metastases and other bone malignancies. Oncotarget. 2015;6:16517\u201326.","journal-title":"Oncotarget"},{"key":"7949_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.157","volume":"6","author":"CS Oliveira","year":"2015","unstructured":"Oliveira CS, Pereira H, Alves S, Castro L, Baltazar F, Chaves SR, et al. Cathepsin D protects colorectal cancer cells from acetate-induced apoptosis through autophagy-independent degradation of damaged mitochondria. Cell Death Dis. 2015;6:e1788.","journal-title":"Cell Death Dis"},{"key":"7949_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.canlet.2012.04.012","volume":"323","author":"YS Hah","year":"2012","unstructured":"Hah YS, Noh HS, Ha JH, Ahn JS, Hahm JR, Cho HY, et al. Cathepsin D inhibits oxidative stress-induced cell death via activation of autophagy in cancer cells. Cancer Lett. 2012;323:208\u201314.","journal-title":"Cancer Lett"},{"key":"7949_CR49","doi-asserted-by":"publisher","first-page":"75774","DOI":"10.18632\/oncotarget.12411","volume":"7","author":"J Fritsch","year":"2016","unstructured":"Fritsch J, Fickers R, Klawitter J, S\u00e4rchen V, Zingler P, Adam D, et al. TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death. Oncotarget. 2016;7:75774\u201389.","journal-title":"Oncotarget"},{"key":"7949_CR50","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1007\/s13277-016-4958-5","volume":"37","author":"B Jancekova","year":"2016","unstructured":"Jancekova B, Ondrouskova E, Knopfova L, Smarda J, Benes P. Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL. Tumour Biol. 2016;37:10685\u201396.","journal-title":"Tumour Biol"},{"key":"7949_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/257414a0","volume":"257","author":"RT Dean","year":"1975","unstructured":"Dean RT. Direct evidence of importance of lysosomes in degradation of intracellular proteins. Nature. 1975;257:414\u20136.","journal-title":"Nature"},{"key":"7949_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbrc.2023.03.016","volume":"655","author":"N Ikari","year":"2023","unstructured":"Ikari N, Arakawa H. Identification of a mitochondrial targeting sequence in cathepsin D and its localization in mitochondria. Biochem Biophys Res Commun. 2023;655:25\u201334.","journal-title":"Biochem Biophys Res Commun"},{"key":"7949_CR53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tibs.2017.01.002","volume":"42","author":"S Hatakeyama","year":"2017","unstructured":"Hatakeyama S. TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis. Trends Biochemical Sci. 2017;42:297\u2013311.","journal-title":"Trends Biochemical Sci"},{"key":"7949_CR54","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1182\/blood-2022-167336","volume":"140","author":"C Ishikawa","year":"2022","unstructured":"Ishikawa C, Barreyro L, Sampson A, Hueneman K, Choi K, Bolanos LC, et al. UBE2N Is a Druggable Target and an Essential Ubiquitin-Conjugating Enzyme in Myeloid Malignancies. Blood. 2022;140:5830.","journal-title":"Blood"},{"key":"7949_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.4247","volume":"23","author":"S G\u00f6llner","year":"2017","unstructured":"G\u00f6llner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017;23:69\u201378.","journal-title":"Nat Med"},{"key":"7949_CR56","doi-asserted-by":"publisher","first-page":"BSR20194334","DOI":"10.1042\/BSR20194334","volume":"40","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Deng T, Ming X, Xu J. TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt\/\u00e1-catenin signaling. Biosci Rep. 2020;40:BSR20194334.","journal-title":"Biosci Rep"},{"key":"7949_CR57","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3324\/haematol.2022.281955","volume":"108","author":"K Zhang","year":"2023","unstructured":"Zhang K, Liu D, Li Y, Shi Z, Guo J, Gao C, et al. The E3 ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia. Haematologica. 2023;108:2116\u201329.","journal-title":"Haematologica"},{"key":"7949_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00448-w","volume":"11","author":"R Vazquez","year":"2021","unstructured":"Vazquez R, Breal C, Zalmai L, Friedrich C, Almire C, Contejean A, et al. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis. Blood Cancer J. 2021;11:62.","journal-title":"Blood Cancer J"},{"key":"7949_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 2024;15:413.","journal-title":"Cell Death Dis"},{"key":"7949_CR60","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1016\/j.bmcl.2014.07.054","volume":"24","author":"U Gr\u00e4dler","year":"2014","unstructured":"Gr\u00e4dler U, Czodrowski P, Tsaklakidis C, Klein M, Werkmann D, Lindemann S, et al. Structure-based optimization of non-peptidic Cathepsin D inhibitors. Bioorg Med Chem Lett. 2014;24:4141\u201350.","journal-title":"Bioorg Med Chem Lett"},{"key":"7949_CR61","doi-asserted-by":"publisher","first-page":"10749","DOI":"10.1021\/jm301630s","volume":"55","author":"Y Liu","year":"2012","unstructured":"Liu Y, Zhang W, Li L, Salvador LA, Chen T, Chen W, et al. Cyanobacterial peptides as a prototype for the design of potent \u03b2-secretase inhibitors and the development of selective chemical probes for other aspartic proteases. J Med Chem. 2012;55:10749\u201365.","journal-title":"J Med Chem"},{"key":"7949_CR62","doi-asserted-by":"publisher","first-page":"115879","DOI":"10.1016\/j.bmc.2020.115879","volume":"29","author":"S Goyal","year":"2021","unstructured":"Goyal S, Patel KV, Nagare Y, Raykar DB, Raikar SS, Dolas A, et al. Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D. Bioorg Med Chem. 2021;29:115879.","journal-title":"Bioorg Med Chem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07949-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T01:30:02Z","timestamp":1757381402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07949-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7949"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07949-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Animal experiments were approved by the Institutional Committee for the Ethics of Animal Care and Treatment in Biomedical Research of CAMS and PUMC (Permit NO. IMB-20240829D501, IMB-20240507D501). Studies involving human patient samples were approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University (Approval No. 2022-KY-1383-002). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"611"}}